The agency first approved the drug in 2014 to treat advanced ovarian cancer in women who stopped responding to at least three previous rounds of chemotherapy. Lynaparza may now be used for the ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.
The FDA also approved a new two-tablet daily treatment regimen for the drug. At present, patients take 8 capsules twice daily.
AstraZeneca in July entered a deal with Merck to develop and commercialize Lynparza separately and in combination with other cancer drugs like Merck’s best-selling immunotherapy, Keytruda, according to Reuters.
More articles on supply chain:
FDA clears Stryker’s spinal screw
7 must-reads for supply chain leaders this week
Mylan finalizes $465 million settlement with DOJ over EpiPen rebates
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
